Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.

Balwit, JM and Kalinski, P and Sondak, VK and Coulie, PG and Jaffee, EM and Gajewski, TF and Marincola, FM (2011) Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. Journal of translational medicine, 9. 60 - ?.

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (427kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Led by key opinion leaders in the field, the 25th Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) provided a scientific platform for ~500 attendees to exchange cutting-edge information on basic, clinical, and translational research in cancer immunology and immunotherapy. The meeting included keynote addresses on checkpoint blockade in cancer therapy and recent advances in therapeutic vaccination against cancer induced by Human Papilloma Virus 16. Participants from 29 countries interacted through oral presentations, panel discussions, and posters on topics that included dendritic cells and cancer, targeted therapeutics and immunotherapy, innate/adaptive immune interplay in cancer, clinical trial endpoints, vaccine combinations, countering negative regulation, immune cell trafficking to tumor microenvironment, and adoptive T cell transfer. In addition to the 50 oral presentations and >180 posters on these topics, a new SITC/iSBTc initiative to create evidence-based Cancer Immunotherapy Guidelines was announced. The SITC/iSBTc Biomarkers Taskforce announced the release of recommendations on immunotherapy biomarkers and a highly successful symposium on Immuno-Oncology Biomarkers that took place on the campus of the National Institutes of Health (NIH) immediately prior to the Annual Meeting. At the Annual Meeting, the NIH took the opportunity to publicly announce the award of the U01 grant that will fund the Cancer Immunotherapy Trials Network (CITN). In summary, the Annual Meeting gathered clinicians and scientists from academia, industry, and regulatory agencies from around the globe to interact and exchange important scientific advances related to tumor immunobiology and cancer immunotherapy.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Balwit, JM
Kalinski, Ppak5@pitt.eduPAK5
Sondak, VK
Coulie, PG
Jaffee, EM
Gajewski, TF
Marincola, FM
Centers: Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date: 14 September 2011
Date Type: Publication
Journal or Publication Title: Journal of translational medicine
Volume: 9
Page Range: 60 - ?
DOI or Unique Handle: 10.1186/1479-5876-9-60
Refereed: Yes
Date Deposited: 28 Oct 2016 17:42
Last Modified: 04 Feb 2019 15:56
URI: http://d-scholarship.pitt.edu/id/eprint/30064

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item